A Phase 1/2a Dose Escalation Study of FF-10501-01 in Patients with Relapsed or Refractory Hematological Malignancies to determine the safety and tolerability. A total of 6 cohorts will be enrolled in Phase 1 to establish the MTD. Phase 2 will consist of 2 cohorts: Cohort 1 will include subjects with high-risk MDS/CMML who have relapsed or are refractory to prior therapy; Cohort 2 will include subjects with AML who have relapsed or are refractory to prior therapy or are ≥ 60 hears of age and not candidates for other therapies.
Clinical Trial: NCT02193958
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies